NCT02316002

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to see how well the experimental drug pembrolizumab (MK-3475) works in people with oligometastatic NSCLC who have already had treatment for their disease. All patients will receive 200 mg of pembrolizumab intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to 8 cycles, and then if their disease is doing well and the study doctor thinks they will benefit patients may receive pembrolizumab for up to 8 more cycles.

Conditions

• Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Interventions

Type	Name	Description
DRUG	Pembrolizumab

Timeline

• Start date: 2015-01-21
• Primary completion: 2018-09-30
• Completion: 2022-12-01
• First posted: 2014-12-12
• Last updated: 2025-11-06
• Results posted: 2019-11-12

Locations

1 site across 1 country: United States